One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study

• Published in: Stem cell research & therapy Vol. 12; no. 1; pp. 340 - 10
• Main Authors: Lu, Jing, Shen, Shan-mei, Ling, Qing, Wang, Bin, Li, Li-rong, Zhang, Wei, Qu, Duo-duo, Bi, Yan, Zhu, Da-long
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.06.2021; BioMed Central; BMC
• Subjects: Adult; Beta cells; Care and treatment; Clinical trials; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - therapy; Diabetes therapy; Dosage; Fasting; Fibroblasts; Glucose; Health aspects; Hematopoietic Stem Cell Transplantation; Humans; Immunoregulation; Insulin; Intravenous administration; Medical research; Medical screening; Medicine, Experimental; Mesenchymal Stem Cell Transplantation - adverse effects; Mesenchymal Stem Cells; Mesenchymal stromal cells; Mesenchyme; Pancreatic beta cells; Peptides; Preservation; Prospective Studies; Remission; Serum levels; Side effects; Stem cells; Stromal cells; Therapeutic targets; Transplantation; Type 1 diabetes; Umbilical Cord; Variables; β cell function; Mesenchymal stromal cells; Transplantation; Type 1 diabetes; β cell function

The preservation or restoration of β cell function in type 1 diabetes (T1D) remains as an attractive and challengeable therapeutic target. Mesenchymal stromal cells (MSCs) are multipotent cells with high capacity of immunoregulation, which emerged as a promising cell-based therapy for many immune di...